Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.51 |
| ▸ | DRD3 | P35462 | 13/20 | 0.51 |
| ▸ | DRD4 | P21917 | 6/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262999 | 0.94 | DRD2 (0.54) | DRD2DRD3DRD4HTR2ASLC6A2 | |
| SCHEMBL5263941 | 0.86 | MEN1 (0.57) | DRD2HTR2ASLC6A4DRD1HTR1A | |
| SCHEMBL5266680 | 0.86 | SLC6A2 (0.47) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL5265422 | 0.84 | ADRA1D (0.57) | DRD2DRD3HTR1AHTR7 | |
| SCHEMBL5270524 | 0.82 | MEN1 (0.54) | DRD2DRD3DRD4HTR1AHTR7 | |
| SCHEMBL5265038 | 0.82 | OPRM1 (0.54) | DRD2DRD3DRD4OPRM1HTR1A | |
| SCHEMBL5265183 | 0.81 | DRD4 (0.48) | DRD2DRD4HTR1AHTR7 | |
| SCHEMBL5270523 | 0.81 | ADRA1B (0.54) | DRD3OPRM1SLC6A4DRD1HTR1A | |
| SCHEMBL5264352 | 0.81 | SMN1; SMN2 (0.55) | DRD2DRD3HTR2ASLC6A4HTR1A | |
| SCHEMBL5264311 | 0.79 | ADRA1D (0.53) | DRD2DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |